Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters

Effective therapy for prion diseases is currently unavailable. Recently, vaccination was shown to be effective in mouse models of a particular neurodegenerative conditions: Alzheimer's disease (AD). Here, we report that vaccination with synthetic oligopeptides homologous to the hamster ( Mesocr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2005-04, Vol.23 (22), p.2862-2868
Hauptverfasser: Magri, Giuliana, Clerici, Mario, Dall’Ara, Paola, Biasin, Mara, Caramelli, Maria, Casalone, Cristina, Giannino, Maria Laura, Longhi, Renato, Piacentini, Luca, Bella, Silvia Della, Gazzuola, Paola, Martino, Piera Anna, Pollera, Claudia, Puricelli, Maria, Servida, Francesco, Crescio, Ines, Boasso, Adriano, Ponti, Wilma, Poli, Giorgio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Effective therapy for prion diseases is currently unavailable. Recently, vaccination was shown to be effective in mouse models of a particular neurodegenerative conditions: Alzheimer's disease (AD). Here, we report that vaccination with synthetic oligopeptides homologous to the hamster ( Mesocricetus auratus) prion protein augments survival time in animals infected intraperitoneally with 263K scrapie agent. For each hamster included in the study, prion-specific serum antibodies as well as deposition of pathological prion protein (PrP res), glial fibrillary acidic protein (GFAP), and mRNA expression for cytokines (TNFα, IL-1β, IL-10) in brain tissues were evaluated. In immunized animals, increased survival after challenge was associated with a reduction of cerebral lesion, PrP deposition and GFAP expression; in these animals, anti-prion protein peptide antibody levels were increased, and the expression of pro-inflammatory cytokines (TNFα and IL-1β) was reduced. Vaccination could be an effective therapeutic approach to postpone disease onset.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.11.067